Ternary Therapeutics lands €4.1M seed round to push AI-designed molecular glues into inflammatory disease

The financing puts another European company into one of biotech’s more closely watched drug-discovery niches: targeted protein degradation. Ternary is focused on molecular glues, a class of small molecules that bring two proteins together in a way that can trigger degradation of disease-driving targets or modulate biology that has been difficult to reach with conventional drugs. The company says its particular emphasis is on inflammation and neuroinflammation, areas where many important targets still sit outside the reach of standard small-molecule approaches.

Ternary’s pitch to investors is that it can make molecular glue discovery less dependent on serendipity. Historically, many such compounds have been found by chance rather than designed prospectively. The company says its platform combines physics-informed AI, molecular dynamics and rapid laboratory validation in a closed loop, using experimental data to refine each successive design cycle.

That proposition appears to have resonated with daphni, which has been building out a stronger science-led investment thesis through its recently closed daphni Blue fund. The French venture capital firm completed the final close of that vehicle at €260 million in January 2026, saying it wants to back startups built on defensible scientific IP emerging from European research. The fund is aimed at early-stage companies spanning biology, chemistry, physics, mathematics and life sciences.

For Ternary, the deal also signals a widening European appetite for techbio platforms that are trying to solve hard modality problems rather than simply apply generic AI tools to drug discovery. The company was incorporated in October 2024, operates from London with lab space at Stevenage Bioscience Catalyst, and says it has already built a preclinical pipeline in immunological disorders.

As part of the announcement, Ternary also said it has appointed Ian Taylor to its board. Taylor served as president of R&D at US-based Arvinas until June 2025. Arvinas is one of the best-known companies in targeted protein degradation, so the appointment gives Ternary added credibility in the field, even if the wider protein degrader space has also faced its share of clinical and commercial setbacks.

Just last week, California-based f5 Therapeutics shut down after six years, with its CEO citing a brutal funding environment for early-stage biotech platforms. None of f5’s programmes had advanced beyond in vivo studies, underlining how difficult it remains to turn excitement around new degradation modalities into durable company building. 

So while Ternary’s seed round is modest by historic techbio standards, it arrives at an important moment. Investors are still willing to fund differentiated platform stories in Europe, but the bar is rising. In molecular glues especially, capital is likely to follow teams that can show not just clever models, but a repeatable engine linking computation to chemistry and biology.

That is the real test for Ternary now. The company has won early backing, added a credible board name and positioned itself in a therapeutically attractive corner of protein degradation. The next question is whether it can translate that platform narrative into partnerable data and, ultimately, clinical candidates.